Dengue vaccine: an update on recombinant subunit strategies

Martín, José Carlos; Hermida, Lisset

doi:10.4149/av_2016_01_3

Cited by 9 publications

(7 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is believed that the massive production of inflammatory cytokines contributes to the pathogenesis of severe dengue disease (Pang et al, 2007 ). Unfortunately, there are no DENV specific therapies or widely available vaccines (Martin and Hermida, 2016 ).…”

Section: Introductionmentioning

confidence: 99%

SIRT6 Acts as a Negative Regulator in Dengue Virus-Induced Inflammatory Response by Targeting the DNA Binding Domain of NF-κB p65

Jin

et al. 2018

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Dengue virus (DENV) is a mosquito-borne single-stranded RNA virus causing human disease with variable severity. The production of massive inflammatory cytokines in dengue patients has been associated with dengue disease severity. However, the regulation of these inflammatory responses remains unclear. In this study, we report that SIRT6 is a negative regulator of innate immune responses during DENV infection. Silencing of Sirt6 enhances DENV-induced proinflammatory cytokine and chemokine production. Overexpression of SIRT6 inhibits RIG-I-like receptor (RLR) and Toll-like receptor 3 (TLR3) mediated NF-κB activation. The sirtuin core domain of SIRT6 is required for the inhibition of NF-κB p65 function. SIRT6 interacts with the DNA binding domain of p65 and competes with p65 to occupy the Il6 promoter during DENV infection. Collectively, our study demonstrates that SIRT6 negatively regulates DENV-induced inflammatory response via RLR and TLR3 signaling pathways.

show abstract

Section: Introductionmentioning

confidence: 99%

SIRT6 Acts as a Negative Regulator in Dengue Virus-Induced Inflammatory Response by Targeting the DNA Binding Domain of NF-κB p65

Jin

et al. 2018

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

show abstract

“…The disease is of growing public health importance in tropical and subtropical areas [ 7 ]. There is no effective antiviral therapy for the disease and a vaccine is still under research [ 8 – 11 ]. At present, vector control remains the cornerstone of prevention and control efforts [ 5 , 10 , 12 – 14 ].…”

Section: Introductionmentioning

confidence: 99%

Insecticide treated curtains and residual insecticide treatment to control Aedes aegypti: An acceptability study in Santiago de Cuba

et al. 2018

View full text Add to dashboard Cite

BackgroundWithin the context of a field trial conducted by the Cuban vector control program (AaCP), we assessed acceptability of insecticide-treated curtains (ITCs) and residual insecticide treatment (RIT) with deltamethrin by the community. We also assessed the potential influence of interviewees’ risk perceptions for getting dengue and disease severity.Methodology/principal findingsWe embedded a qualitative study using in-depth interviews in a cluster randomized trial (CRT) testing the effectiveness of ITCs and RIT in Santiago de Cuba. In-depth interviews (N = 38) were conducted four and twelve months after deployment of the tools with people who accepted the tools, who stopped using them and who did not accept the tools. Data analysis was deductive. Main reasons for accepting ITCs at the start of the trial were perceived efficacy and not being harmful to health. Constraints linked to manufacturer instructions were the main reason for not using ITCs. People stopped using the ITCs due to perceived allergy, toxicity and low efficacy. Few heads of households refused RIT despite the noting reasons for rejection, such as allergy, health hazard and toxicity. Positive opinions of the vector control program influenced acceptability of both tools. However, frequent insecticide fogging as part of routine AaCP vector control actions diminished perceived efficacy of both tools and, therefore, acceptability. Fifty percent of interviewees did feel at risk for getting dengue and considered dengue a severe disease. However, this did not appear to influence acceptability of ITCs or RIT.Conclusion/significanceAcceptability of ITCs and RIT was linked to acceptability of AaCP routine vector control activities. However, uptake and use were not always an indication of acceptability. Factors leading to acceptability may be best identified using qualitative methods, but more research is needed on the concept of acceptability and its measurement.

show abstract

“…Several dengue vaccine candidates are in the pipeline. There are live-attenuated and inactivated viruses, DNA constructs, vector-based expression, virus-like particles and recombinant subunit antigens [48][49][50]. In 2016, the first commercial dengue vaccine called Dengvaxia® has been registered in several endemic dengue countries including Mexico, Brazil, and Philippines [44,51].…”

Section: Dengue Vaccine Developmentmentioning

confidence: 99%

“…Another variety of current dengue vaccine candidates involves recombinant DNA technology. There are recombinant subunit vaccines requiring expression systems such as plasmid DNA, heterologous vectors, virus-like particles based on the co-expression of the prM and E proteins or only displaying EDIII of the four serotypes, and purified recombinant viral antigens [34,43,[47][48][49][50][75][76][77]. Most dengue vaccine candidates are in preclinical studies or still in Phase I clinical trials.…”

Section: Dengue Vaccine Involving Dna Technologymentioning

confidence: 99%

Dengue: a growing threat requiring vaccine development for disease prevention

Bos

Gadéa

Desprès

2018

Pathogens and Global Health

View full text Add to dashboard Cite

Dengue disease is the most prevalent mosquito-borne viral infection in humans. At least one half of the global population is estimated at risk of infection and an estimated 390 million people are infected each year. Over the past few years, dengue burden continued to increase, mainly impacting developing countries. Alarming changes in dengue epidemiology were observed highlighting a spread from tropical to subtropical regions as well as urban to rural areas. An increase in the co-infections with the four serotypes has also been noticed, involving a shift in the targeted population from pediatric to adult. Facing these global changes, authorities will have to reinforce preventive actions and adapt healthcare management. New prophylactic strategies are urgently needed to prevent severe forms of dengue disease. The lack of specific antiviral therapies available turns vaccine development into a socio-economic challenge. In this review, we propose an update on the dengue global trends and different vaccine strategies in development. A particular attention will be paid to up-to-date information on dengue transmission and the protective efficacy of newly commercialized tetravalent dengue vaccine Dengvaxia®, as well as the most advanced candidate vaccines in clinical development.

show abstract

Dengue vaccine: an update on recombinant subunit strategies

Cited by 9 publications

References 77 publications

SIRT6 Acts as a Negative Regulator in Dengue Virus-Induced Inflammatory Response by Targeting the DNA Binding Domain of NF-κB p65

SIRT6 Acts as a Negative Regulator in Dengue Virus-Induced Inflammatory Response by Targeting the DNA Binding Domain of NF-κB p65

Insecticide treated curtains and residual insecticide treatment to control Aedes aegypti: An acceptability study in Santiago de Cuba

Dengue: a growing threat requiring vaccine development for disease prevention

Contact Info

Product

Resources

About